Search

Patients
EXPLORE PATIENTS
Fight Cancer Smarter
Patient Services
Share Your Story
What is a Biomarker?
Talk to Your Physician
Find a Doctor
Patient Stories
Testing Consent
Financial Services
Pay Your Bill
Fight Cancer Smarter
What is a Biomarker?
Patient Services
Talk to Your Physician
Find a Doctor
Patient Stories
Testing Consent
Financial Services
Pay Your Bill
Share Your Story
Physicians
EXPLORE PHYSICIANS
Physician Tests
Physician Services
TISSUE PROFILING
MI Profile
MI Cancer Seek
MI Tumor Seek Hybrid
BLOOD PROFILING
Caris Assure
AI SIGNATURES
Caris GPSai
Caris FOLFIRSTai
Caris Molecular Tumor Board
Customer Support
Right-In-Time Trials
Physician Tests
TISSUE PROFILING
MI Profile
MI Cancer Seek
MI Tumor Seek Hybrid
BLOOD PROFILING
Caris Assure
AI SIGNATURES
Caris GPSai
Caris FOLFIRSTai
Physician Services
Caris Molecular Tumor Board
Customer Support
Right-In-Time Trials
Biopharma
EXPLORE BIOPHARMA
Core Services
Multimodal Data
Caris Discovery
Molecular Profiling
Clinical Trial Matching
Commercialization
Core Services
Molecular Profiling
Clinical Trial Matching
Commercialization
Multimodal Data
Caris Discovery
Research
EXPLORE RESEARCH
Publications
Artificial Intelligence
Product Pipeline
Manuscripts
Posters
Presentations
Abstracts
Caris CODEai
Nanoverse
QUANTUMai Report
Publications
Manuscripts
Posters
Presentations
Abstracts
Artificial Intelligence
Caris CODEai
Nanoverse
QUANTUMai Report
Product Pipeline
Partners
EXPLORE PARTNERS
Caris POA
EHR Integrations
International Distributors
Members
Leadership
Working Groups
Fellows Forum
Caris POA
Members
Leadership
Working Groups
Fellows Forum
EHR Integrations
International Distributors
News & Events
EXPLORE
News
Events
Media Library
Podcasts
Webinars
News
Events
Media Library
Podcasts
Webinars
LATEST NEWS

Caris Life Sciences Announces Pricing of Initial Public Offering

June 2025

Caris Life Sciences Announces Launch of Initial Public Offering

June 2025
About
EXPLORE ABOUT
Careers
Leadership
Locations
Contact Us
Investors
Opportunities
Our People
Benefits
Careers
Opportunities
Our People
Benefits
Leadership
Locations
Contact Us
Investors

MI Cancer Seek® is now available for clinical ordering. Learn more.

Home / Pathology Ad Board Registration Survey

Pathology Ad Board Registration Survey

Please complete the brief survey below to help us tailor this and future ad boards:

Name(Required)

First Last

Email (institutional email addresses only)(Required)

Institution(Required)

Please upload your CV(Required)

Max. file size: 4 GB.

Indicate your top 3 topics of interest for the Advisory Board(Required)

Pathology advancements and challenges in tissue-based molecular profiling

Advancements in blood-based molecular profiling

How does smart implementation of AI help?

Intended use of molecular profiling in CNS tumors

Intended use of molecular profiling in Sarcoma tumors

Intended use of molecular profiling in pediatric tumors

Digital Pathology

How to keep updated on FDA approvals, therapy guidelines, and indications for molecular profiling

Identify potential improvements and innovations in molecular profiling

Interest in Caris’ future product pipeline

Other:

Other:

Does your current institutional policy allow you to reflexively order next-generation sequencing (NGS) testing?(Required)

Yes

No

Not sure

In development

Would the ability to reflexively order comprehensive molecular profiling enhance patient care and support your oncologists in clinical decision-making?(Required)

Yes

No

What barriers, if any, currently prevent you from reflexively ordering comprehensive molecular profiling?(Required)

Which of the following factors limit your ability to reflexively order comprehensive molecular profiling? (Select all that apply)(Required)

Institutional policies or guidelines

Insurance or reimbursement issues

Lack of clinical indication at time of diagnosis

Limited access to testing platforms

Concern about overuse or appropriateness

Other (please specify):

Other:

In which types of cancer do you believe reflexive molecular profiling provides the most benefit? (Select all that apply)(Required)

NSCLC

Colorectal

Breast

Pancreatic

Glioblastoma

Unknown primary

Other (please specify):

Other:

How feasible would it be to implement reflexive comprehensive molecular profiling in your current workflow?(Required)

Very feasible

Somewhat feasible

Neutral

Somewhat difficult

Very difficult

Would having automated criteria or algorithms for reflexive ordering improve adoption and consistency?(Required)

Yes

No

Not sure

How often do you recommend liquid biopsy when tissue is insufficient for molecular profiling?

Always

Often

Sometimes

Rarely

Never

What are the main factors that influence your decision to recommend or not recommend liquid biopsy in cases of insufficient tissue? (Select all that apply)(Required)

Limited clinical utility or evidence

Concerns about test sensitivity/specificity

Institutional or lab policy restrictions

Institutional or lab policy restrictions

Oncologist preference or workflow

Test availability or turnaround time

Lack of familiarity or training

Other (please specify):

Other:

When you recommend liquid biopsy what is your preferred communication method?(Required)

Verbally

Noted in path report

Other:

Other:

Beyond providing accurate and timely results, and being a good steward of your tissue, what else would you like your NGS partner to provide?(Required)

Pathology Education

Patient Education

Molecular Tumor Board

Ease of use/Integration

Trial Matching

Research Support

Other (please specify):

Other:

Do you routinely submit cytology specimens (e.g., FNA smears, cell blocks, body fluids) for next-generation sequencing (NGS) testing?(Required)

Yes

No

Sometimes (please specify circumstances)

Not applicable to my practice

Optional comment box: Please provide any additional details or challenges you've encountered with using cytology for NGS.

In your experience, how often are cytology specimens adequate for successful NGS testing?(Required)

Always (>90%)

Often (70–90%)

Sometimes (30–69%)

Rarely (<30%)

Unsure

What are the most common challenges you encounter when using cytology specimens for NGS? (Select all that apply)(Required)

Insufficient cellularity

Poor DNA/RNA quality

Lack of validated protocols for cytology

Rejection by external labs due to specimen type

Long turnaround time

Cost/reimbursement issues

Other (please specify):

Other:

Does your institution/lab have validated protocols for performing NGS on cytology specimens?(Required)

Yes, for all types of cytology specimens

Yes, but only for certain types (e.g., cell blocks)

No

Not sure

Δ

Patients
Physicians
Biopharma
Research

Partners
International Distributors
Licenses & Accreditations

News & Events
Careers
IP

Connect with Us

Facebook
LinkedIn
X

©2025 Caris Life Sciences. All Rights Reserved.

Privacy & Website Policies

Terms & Conditions

Annual Notice to Physicians